|Event Name||2016 SITC 31st Annual Meeting
Wednesday, November 09, 2016
Sunday, November 13, 2016
Gaylord National Hotel & Convention Center
|Cost||$175 - $1,600
The SITC 31st Annual Meeting provides a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consists of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting includes updates on major national and international initiatives coming from academia, government and industry, as well as important Society projects.
Following SITC’s tradition of collaborating to advance the field, the 31st Annual Meeting features numerous sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. An in-depth Value of Cancer Immunotherapy Summit, organized in collaboration with the American Society of Clinical Oncology, is prominently featured to discuss a crucial topic that impacts all cancer immunotherapy constituents, from researchers and clinicians to payers and cancer patients.
The audience includes U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This includes, but is not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.
Upon completion of this meeting, participants are now able to:
• Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research
• Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy
• Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic interventions